A New Drug Just Became the First Approved for Both Active and Chronic Thyroid Eye Disease

FDA approved veligrotug (Lumvoa) for both active and chronic thyroid eye disease — a first. Here’s who qualifies, what the evidence shows, and what changes for the 50,000–100,000 Americans affected annually.